Table 5 Baseline demographics and clinical characteristics, including CV risk factors for the CHF analysis (of investigator-reported events)
|  | Linagliptin (n = 5488) | Placebo (n = 3290) |
|---|---|---|
Gender, % of patients Male/female | 53.5/46.5 | 54.9/45.1 |
Age, years | 58.2 ± 10.6 | 58.1 ± 10.6 |
BMI, kg/m2 | 29.3 ± 5.3 | 30.0 ± 5.4 |
Race, % of patients | ||
White | 59.5 | 63.0 |
Black | 4.3 | 7.4 |
Asian | 36.2 | 29.6 |
HbA1c, mmol/mol | 66.1 ± 9.8 | 66.1 ± 9.8 |
HbA1c, % | 8.2 ± 0.9 | 8.2 ± 0.9 |
FPG, mg/dL | 166.2 ± 45.7 | 168.2 ± 47.4 |
Diabetes duration, % of patients | ||
≤1 year | 15.4 | 15.8 |
1–5 years | 30.6 | 30.3 |
>5Â years | 53.9 | 53.7 |
Missing | 0.1 | 0.2 |
Antidiabetes drugs at enrolment, % of patients | ||
None | 21.7 | 25.6 |
1 | 38.9 | 39.1 |
2 | 38.1 | 33.5 |
≥3 | 1.2 | 1.7 |